ReviewSignal transduction and targeted therapy2026
Aging and cancer: current understandings and future perspectives.
Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Deciphering the mechanistic links between aging and cancer remains a central challenge in biomedical research. This review begins by presenting recent epidemiological data on cancer incidence across age groups, underscoring the complex and paradoxical interplay between aging and cancer. A systematic analysis follows four core signaling pathways that underpin both aging and cancer: (i) nutrient sensing and energy metabolism pathways, (ii) stress response and genome maintenance pathways, (iii) inflammatory and microenvironmental pathways, and (iv) sirtuin-mediated epigenetic and transcriptional modulation pathways. Each pathway is analyzed regarding its distinct and overlapping roles in aging and cancer, with exploration of strategies for comodulating these shared mechanisms to simultaneously mitigate both conditions. Established and emerging druggable targets within these pathways are highlighted, offering new perspectives for future therapeutic development. Current integrative strategies to achieve concurrent antiaging and anticancer effects include targeting cellular nutrient sensing and metabolism, enhancing genomic integrity, suppressing chronic inflammation, clearing senescent cells, and modulating epigenetic programs. Finally, the impact of aging on cancer therapy, particularly immunotherapy, is discussed, along with a review of representative aging-related pathways and genes and their roles in modulating immunotherapy efficacy. Analysis of agents targeting each pathway spanning preclinical studies, clinical trials, and clinically approved drugs reveals disparities in the research progress between anti-aging and anticancer applications. Consequently, a promising future strategy for drug discovery lies in repurposing well-established anticancer agents for antiaging interventions, as well as translating insights from aging research into novel antitumor therapies, thereby achieving synergistic benefits in both fields.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.